Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Kansas Beqvez Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of KansasPolicy N/A

    Beqvez (fidanacogene elaparvovec-dzkt)

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for a single intravenous dose of Beqvez for adults with moderate to severe congenital factor IX deficiency. It applies to BCBS Kansas members and BCBS Kansas-administered self-insured plans, subject to member benefits, contracts, and applicable mandates.

    Policy Summary
    PayerBlue Cross Blue Shield of Kansas
    PolicyBeqvez (fidanacogene elaparvovec-dzkt)
    Policy CodePolicy N/A
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateFebruary 24, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation for every Beqvez request.
    SourceLink
    POLICY UPDATE CHANGES

    The policy updated administrative wording for initial and renewal authorization periods, initial criteria, and prior authorization validity.

    1 doseAuthorization limit
    18+Minimum age
    ≤2%Factor IX activity
    <0.6 BUInhibitor titer

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5 × 10^11 vg/kg
    Treatment dose
    1 unitBillable unit limit

    Coverage Criteria

    Initial therapy for adult congenital hemophilia B

    Covered when all of the following are met, including at least one qualifying treatment or bleeding criterion:

    Initial approval criteria

    • Patient and diagnosis

      • The patient is at least 18 years of age and has moderate to severe congenital factor IX deficiency confirmed by blood coagulation testing.Age ≥18; factor IX activity ≤2% of normal circulating factor IX
    • Prior gene therapy and treatment history

      • The patient has not received prior hemophilia AAV-vector-based gene therapy.
    • ONE of the following qualifying treatment or bleeding criteria

      • The patient currently uses continuous routine factor IX prophylaxis therapy, unless there is a contraindication or intolerance.

        Continuous routine prophylaxis is treatment administered at an a priori defined infusion frequency documented in the medical record.

      • The patient has a current or historical life-threatening hemorrhage.
      • The patient has repeated serious spontaneous bleeding episodes.

        Examples include intramuscular hematomas requiring hospitalization, hemarthrosis, central nervous system bleeding, pulmonary hemorrhage, life-threatening gastrointestinal hemorrhage, or umbilical cord bleeding.

    • Inhibitor status

      • The patient has a negative factor IX inhibitor titer and no prior history of factor IX inhibitors.<0.6 Bethesda Units

        If the test result is positive, repeat testing is required in approximately 2 weeks. If repeat testing remains positive, fidanacogene elaparvovec should not be given.

    • Safety and monitoring

      • The patient tests negative for AAVRh74var neutralizing antibodies using an FDA-approved or CLIA-compliant test.
      • Baseline liver function will be assessed before treatment and liver function will be monitored after treatment according to the product-labeling schedule, with corticosteroids administered in response to elevations.
      • Patients with preexisting hepatocellular carcinoma risk factors will receive abdominal ultrasound screening and regular monitoring for alpha-fetoprotein elevations after administration.

        Risk factors include cirrhosis, advanced hepatic fibrosis, hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, and advanced age.

    • Exclusions and counseling

      • The patient does not have current liver-related coagulopathy, hypoalbuminemia, persistent jaundice, cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy, hepatic fibrosis, or active viral hepatitis.
      • The patient has been tested for HIV and does not have an active infection.Active HIV: CD4+ count <200/mm³ or viral load ≥20 copies/mL with serologic evidence of HIV-1 or HIV-2 infection
      • The patient has been counseled to avoid potentially hepatotoxic substances, such as alcohol, which may reduce treatment efficacy.

    Renewal limitations

    Renewal is limited to the following condition:

    Renewal limitation: The duration of authorization has not been exceeded.

    Renewal authorization may not be provided. The authorization is limited to one dose and one billable unit, and its duration may not be renewed.

    Coverage is excluded for patients with current liver-related coagulopathy, hypoalbuminemia, persistent jaundice, cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy, hepatic fibrosis, or active viral hepatitis. Patients with preexisting hepatocellular carcinoma risk factors may require enhanced post-treatment surveillance, including abdominal ultrasound and alpha-fetoprotein monitoring.

    Coverage is excluded for patients who have received prior hemophilia AAV-vector gene therapy, have a history of factor IX inhibitors, or have persistently positive factor IX inhibitor testing. The required factor IX inhibitor titer is <0.6 Bethesda Units; if the initial test is positive, testing must be repeated in approximately 2 weeks, and treatment should not be given if the repeat test remains positive.

    Patients must be tested for HIV and may not have an active HIV infection. Under the policy, active infection is defined as a CD4+ cell count below 200/mm³ or an HIV viral load of at least 20 copies/mL in a patient with serologic evidence of HIV-1 or HIV-2 infection.

    Billing Codes and Clinical Thresholds

    HCPCS codeHCPCSCovered
    J1414Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose; 1 billable unit = 1 kit
    NDC(s)NDCCovered
    00069-2004-04Beqvez multi-vial kit; patient dose weight ≤75 kg; 4 vials per kit
    00069-2005-05Beqvez multi-vial kit; patient dose weight >75 to ≤95 kg; 5 vials per kit
    00069-2006-06Beqvez multi-vial kit; patient dose weight >95 to ≤115 kg; 6 vials per kit
    00069-2007-07Beqvez multi-vial kit; patient dose weight >115 to ≤135 kg; 7 vials per kit
    Removed inactive HCPCS codesHCPCS
    J3590Inactive HCPCS code removed from the policy
    C9172Inactive HCPCS code removed from the policy
    Factor IX activity
    Required factor IX activity≤2% of normal circulating factor IX
    Applicable conditionModerate to severe congenital factor IX deficiency
    ConfirmationConfirmed by blood coagulation testing
    Factor IX inhibitor titer
    Required inhibitor titer<0.6 Bethesda Units
    Inhibitor historyNo prior history of factor IX inhibitors
    If test is positive

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Beqvez requests. Submit the request with the supporting clinical documentation needed to evaluate medical necessity; the initial authorization is limited to one dose.

    • Authorization validity is provided only when the applicable approval criteria are met.
    • Submit requests through the PA web portal by direct upload or by fax.
    Billing Rule

    One-Time, Nonrenewable Authorization

    Authorization is limited to one dose and one billable unit. The authorization cannot be renewed, and additional doses or units are not authorized under this policy.

    Therapy Background

    Beqvez (fidanacogene elaparvovec-dzkt) is an adeno-associated virus vector-based gene therapy used for adults with moderate to severe congenital hemophilia B caused by factor IX deficiency. The policy requires baseline safety assessment, including factor IX inhibitor, AAVRh74var neutralizing antibody, liver, and HIV testing, followed by monitoring of factor IX activity and liver safety. Exogenous factor IX may remain necessary until an adequate treatment response occurs and may still be needed for surgery, invasive procedures, trauma, or bleeding when treatment-derived factor IX is insufficient.

    Policy Definitions

    Dose weight
    BMI ≤30 kg/m²Dose weight equals actual body weight
    BMI >30 kg/m²Dose weight is calculated using 30 kg/m² × [height (m)]²
    PurposeDose weight is used to calculate the Beqvez treatment dose
    Continuous routine factor IX prophylaxis
    DefinitionTreatment administered at an a priori defined frequency of infusions
    ExamplesTwice weekly or once every two weeks
    DocumentationThe infusion frequency must be documented in the medical records

    Initial Authorization Criteria

    Initial authorization

    Initial authorization is covered when all of the following patient, diagnosis, treatment history, safety, and monitoring criteria are met:

    Initial authorization criteria

    • Patient and diagnosis: The patient is at least 18 years of age and has moderate to severe congenital factor IX deficiency confirmed by blood coagulation testing.Age ≥18; factor IX activity ≤2% of normal circulating factor IX
    • ONE qualifying treatment or bleeding criterion

      • The patient is on continuous routine factor IX prophylaxis, unless contraindicated or intolerant.
      • The patient currently uses factor IX prophylaxis therapy.

    Post-Treatment Monitoring and Continuation

    Continuation and response monitoring

    After treatment, all of the following monitoring and replacement requirements apply:

    Post-treatment management

    • Factor IX activity is monitored periodically after treatment, including weekly monitoring for approximately 3 months as an example, and factor IX inhibitors are assessed if bleeding is not controlled.
    • Exogenous factor IX is continued until a response to fidanacogene elaparvovec occurs.
    • Factor IX prophylaxis is discontinued when treatment-derived factor IX levels reach 5%.5% factor IX activity
    • Exogenous factor IX or other hemostatic products remain available when needed for surgery, invasive procedures, trauma, or bleeding if treatment-derived factor IX activity is insufficient for adequate hemostasis.

    Step Therapy Requirement

    StepRequirementAlternative qualifying history
    1Continuous routine factor IX prophylaxis, administered at a predefined infusion frequency, is required unless contraindicated or intolerant.Alternatively, the patient must have a current or historical life-threatening hemorrhage or repeated serious spontaneous bleeding episodes, including events such as hospitalization-requiring intramuscular hematomas, hemarthrosis, CNS bleeding, pulmonary hemorrhage, life-threatening GI hemorrhage, or umbilical cord bleeding.

    Dose and Authorization Limits

    Beqvez quantity limit
    Quantity limit1 billable unit for one dose
    Initial authorizationPrior authorization validity is provided initially for one dose
    RenewalPrior authorization validity may not be renewed
    Policy Summary
    PayerBlue Cross Blue Shield of Kansas
    PolicyBeqvez (fidanacogene elaparvovec-dzkt)
    Policy CodePolicy N/A
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateFebruary 24, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation for every Beqvez request.
    SourceLink
    On This Page
    Coverage CriteriaBilling Codes and Clinical ThresholdsAuthorization and Documentation RequirementsTherapy BackgroundPolicy DefinitionsInitial Authorization CriteriaPost-Treatment Monitoring and ContinuationStep Therapy RequirementDose and Authorization Limits
    Retest within approximately 2 weeks; if repeat testing is also positive, fidanacogene elaparvovec should not be given
    Factor IX activity for prophylaxis discontinuation
    Discontinuation thresholdFactor IX levels of 5% from fidanacogene elaparvovec treatment
    Before response occursContinue exogenous factor IX until treatment response occurs
    MonitoringMonitor factor IX activity periodically, such as weekly for 3 months
    Treatment dose
    Recommended dose5 × 10^11 vector genomes per kg of body weight
    AdministrationSingle-dose intravenous infusion
    Dose basisDose is calculated using the patient’s dose weight
    BMI dose-weight threshold
    BMI threshold30 kg/m²
    BMI at or below thresholdUse actual body weight as the dose weight
    BMI above thresholdUse adjusted dose weight calculated as 30 kg/m² × [height (m)]²
  1. Initial authorization: one dose.
  2. Maximum quantity: 1 HCPCS billable unit per dose and over time.
  3. Renewal: not permitted.
  4. Documentation Required

    Factor IX Prophylaxis or Qualifying Bleeding History

    Document that the patient has moderate to severe congenital factor IX deficiency and is receiving continuous routine factor IX prophylaxis, unless prophylaxis is contraindicated or not tolerated. The patient must also currently use factor IX prophylaxis or have qualifying serious or life-threatening bleeding history.

    • Patient must be at least 18 years of age.
    • Factor IX activity must be ≤2% of normal circulating factor IX, confirmed by blood coagulation testing.
    • Continuous routine prophylaxis means treatment at an a priori defined infusion frequency documented in the medical record.
    • Qualifying history includes current factor IX prophylaxis, current or historical life-threatening hemorrhage, or repeated serious spontaneous bleeding such as hospitalization-requiring intramuscular hematomas, hemarthrosis, CNS or intracranial bleeding, pulmonary hemorrhage, life-threatening GI hemorrhage, or umbilical cord bleeding.
    Documentation Required

    Required Clinical Documentation

    Include the medical records necessary to establish medical necessity. Records are reviewed when submitted as part of the authorization evaluation.

    • Submit medical records, chart notes, laboratory results, and confirmatory diagnostic testing.
    • Include diagnosis, step-therapy history, and applicable clinical markers, including genetic or mutational testing supporting initiation.
    • Provide documentation by direct upload through the PA web portal or by fax.
    Documentation Required

    Hemophilia B and Inhibitor Records

    Document negative factor IX inhibitor testing and the absence of a prior inhibitor history. If the initial inhibitor test is positive, repeat testing in approximately two weeks; if the repeat test remains positive, fidanacogene elaparvovec should not be administered.

    • Factor IX inhibitor titer must be <0.6 Bethesda Units.
    • Confirm the diagnosis by blood coagulation testing.
    • Document continuous routine factor IX prophylaxis history or the applicable contraindication or intolerance.
    Documentation Required

    Pre-Treatment Safety Assessment

    Complete and document the pre-treatment safety assessment before administration. This includes AAVRh74var antibody testing, liver and HIV assessment, required risk-based surveillance, and patient counseling.

    • Patient must be negative for AAVRh74var neutralizing antibodies using an FDA-approved or CLIA-compliant test.
    • Assess baseline liver function before therapy and plan post-treatment monitoring according to product labeling; administer corticosteroids in response to elevations.
    • For patients with hepatocellular carcinoma risk factors, arrange abdominal ultrasound and regular, such as annual, alpha-fetoprotein monitoring.
    • Test for HIV and document no active infection; in patients with serologic evidence of HIV-1 or HIV-2, active infection includes CD4+ count <200/mm³ or viral load ≥20 copies/mL.
    • Counsel the patient to avoid potentially hepatotoxic substances, including alcohol, that may reduce treatment efficacy.

    Unsupported block type: documentation

    Denial Risk

    Missing Supporting Documentation

    Failure to submit the required medical records and clinical documentation may result in denial because medical necessity cannot be established under the policy.

    • Missing records include medical records, chart notes, laboratory results, confirmatory diagnostics, diagnosis, step-therapy documentation, and applicable genetic or mutational testing.
    • Submit all supporting documentation with the authorization request through the PA web portal or by fax.
    Denial Risk

    Failure to Meet Clinical Criteria

    Requests may be denied when the clinical criteria are not met or are not adequately documented. Confirm all age, diagnosis, factor IX activity, prophylaxis, bleeding-history, and treatment-response requirements before submission.

    • Patient must be at least 18 years old with moderate to severe congenital factor IX deficiency, defined as ≤2% of normal factor IX activity.
    • Continuous routine factor IX prophylaxis is required unless contraindicated or not tolerated.
    • The patient must have current factor IX prophylaxis or qualifying life-threatening or repeated serious spontaneous bleeding history.
    • The patient must discontinue prophylaxis after achieving factor IX levels of 5% from treatment.
    Denial Risk

    Liver-Related Contraindicating Conditions

    Coverage is precluded when specified liver-related contraindicating conditions are present. Document the liver assessment and confirm that none of these conditions applies before treatment.

    • No current liver-related coagulopathy, hypoalbuminemia, persistent jaundice, or cirrhosis.
    • No portal hypertension, splenomegaly, hepatic encephalopathy, hepatic fibrosis, or active viral hepatitis.
    • Assess baseline and post-treatment liver function according to product labeling, with corticosteroids for elevations.
    • Patients with cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age require abdominal ultrasound and regular AFP monitoring; these risk factors must be addressed in the safety assessment.
    Denial Risk

    Prior Gene Therapy or Inhibitors

    Requests may be denied when the patient has received prior hemophilia AAV-vector gene therapy, has a history of factor IX inhibitors, or has persistently positive inhibitor testing.

    • Document no prior hemophilia AAV-vector gene therapy, such as etranacogene dezaparvovec.
    • Document negative factor IX inhibitor titers (<0.6 Bethesda Units) and no prior inhibitor history.
    • If inhibitor testing is positive, repeat the test in approximately two weeks; persistent positivity means fidanacogene elaparvovec should not be given.
    Negative factor IX inhibitor titer
    Negative titer thresholdBelow 0.6 Bethesda Units
    Required statusPatient must test negative for factor IX inhibitor titers
    Additional requirementPatient must not have a prior history of factor IX inhibitors
  5. The patient has a current or historical life-threatening hemorrhage.
  6. The patient has repeated serious spontaneous bleeding episodes.
  7. Treatment history and inhibitor status

    • The patient has not received prior hemophilia AAV-vector-based gene therapy.
    • The patient has a negative factor IX inhibitor titer and no prior history of inhibitors.<0.6 Bethesda Units

      If testing is positive, repeat testing in approximately 2 weeks. Treatment should not be given if repeat testing remains positive.

  8. Safety and monitoring

    • The patient is negative for AAVRh74var neutralizing antibodies, as determined by an FDA-approved or CLIA-compliant test.
    • Baseline liver function will be assessed before treatment and liver function will be monitored after treatment according to the product-labeling schedule, with corticosteroids administered in response to elevations.
    • Patients with preexisting hepatocellular carcinoma risk factors will receive abdominal ultrasound screening and regular alpha-fetoprotein monitoring after administration.
    • The patient does not have the specified liver-related contraindicating conditions or active viral hepatitis.
    • The patient has been tested for HIV and does not have an active infection.Active HIV: CD4+ count <200/mm³ or viral load ≥20 copies/mL with serologic evidence of HIV-1 or HIV-2 infection
    • The patient has been counseled to avoid potentially hepatotoxic substances, such as alcohol.
  9. Post-treatment plan

    • The treatment plan includes periodic monitoring of factor IX activity and continued exogenous factor IX until an adequate treatment response occurs.
    • Factor IX prophylaxis will be discontinued when treatment-derived factor IX levels reach 5%.5% factor IX activity
  10. Use of exogenous factor IX before and after administration may impede assessment of endogenous, treatment-derived factor IX activity.